Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the ...

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of ...